Review Article: Is it time to embrace haemodiafiltration for centre-based haemodialysis?

Nephrology

Volumn 13, Issue 4, 2008, Pages 269-277

  Petrie, James J B ^a   Ng, Tsun G ^a   Hawley, Carmel M ^a,b  

^a PRINCESS ALEXANDRA HOSPITAL   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Haemodiafiltration; Haemodialysis; Haemofiltration

Indexed keywords

CLINICAL TRIAL; DIALYSATE; DIALYSIS MEMBRANE; HEMODIAFILTRATION; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; INTERMETHOD COMPARISON; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZATION; REVIEW; SURVIVAL; TECHNIQUE; TECHNOLOGY; TREATMENT DURATION;

EVIDENCE-BASED MEDICINE; HEMODIAFILTRATION; HEMODIALYSIS SOLUTIONS; HEMODIALYSIS UNITS, HOSPITAL; HISTORY, 20TH CENTURY; HUMANS; KIDNEY DISEASES; RENAL DIALYSIS; TREATMENT OUTCOME;

EID: 43449107655     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/j.1440-1797.2008.00964.x     Document Type: Review

References (69)

1. Pierratos A, Ouwendyk M, Francoeur R et al. Nocturnal hemodialysis: three-year experience. J. Am. Soc. Nephrol. 1998 9 : 859 68.
2. Lindsay RM. The London, Ontario, daily/nocturnal hemodialysis study. Semin. Dial 2004 17 : 85 91.
3. Agar JM, Somerville CA, Dwyer KM et al. Nocturnal hemodialysis in Australia. Hemodial. Int. 2003 7 : 278 89.
4. Eknoyan G, Beck GJ, Cheung AK et al. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N. Engl. J. Med. 2002 347 : 2010 19.
5. Canaud B, Bragg-Gresham JL, Marshall MR et al. Mortality risk for patients receiving haemodiafiltration versus haemodialysis. Kidney Int. 2006 69 : 2087 93.
6. Jirka T, Cesare S, Benedetto D et al. Mortality risk for patients receiving hemodiafiltration versus haemodialysis. Kidney Int. 2006 70 : 1524.
7. Russ G. ANZDATA Registry Report 2005. Adelaide : Australia and New Zealand Dialysis and Transplant Registry, 2005.
8. Canaud B, Morena M, Leray-Moragues H, Chalabi L, Cristo JP. Overview of clinical studies in hemodiafiltration: what do we need now Hemodial. Int. 2006 10 (Suppl. 1 S5 S12.
9. Vanholder R, Smet RD, Glorieux G et al. Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int. 2003 63 : 1934 43.
10. Scribner BH, Babb AL. Evidence for toxins of 'middle' molecular weight. Kidney Int. Suppl. 1975 3 : 349 51.
11. Babb AL, Popovich RP, Christopher TG, Scribner BH. The genesis of the square metre hour hypothesis. Trans. Am. Soc. Artf. Intern. Organs. 1971 17 : 81 91.
12. Milutinovic J, Babb AL, Eschbach JW et al. Uremic neuropathy: evidence of middle molecule toxicity. Artif. Organs. 1978 2 : 45 51.
13. Lowrie EG, Laird NM, Parker TF, Sargent JA. Effect of the hemodialysis prescription of patient morbidity: report from the National Cooperative Dialysis Study. N. Engl. J. Med. 1981 305 : 1176 81.
14. Gotch FA, Sargent JA. A mechanistic analysis of the National Cooperative Dialysis Study (NCDS). Kidney Int. 1985 28 : 526 34.
15. Held PJ, Levin NW, Bovbjerg RR, Pauly MV, Diamond LH. Mortality and duration of haemodialysis treatment. JAMA 1991 265 : 871 5.
16. Marshall MR, Byrne BG, Kerr PG, McDonald SP. Associations of hemodialysis dose and session length with mortality risk in Australian and New Zealand patients. Kidney Int. 2006 69 : 1229 32.
17. Saran R, Bragg-Gresham JL, Levin NW et al. Longer treatment time and slower ultrafiltration in hemodialysis: associations with reduced mortality in the DOPPS. Kidney Int. 2006 69 : 1222 31.
18. Henderson LW. The Beginning of Clinical Hemofiltration: a Personal Account. ASAIO J. 2003 49 : 513 17.
19. Schaefer K, Asmus G, Quellhorst E, Pauls A, von Herrath D, Jahnke J. Optimum dialysis treatment for patients over 60 years with primary renal disease. Survival data and clinical results from 242 patients treated either by haemodialysis or haemofiltration. Proc EDTA-ERA 1984 21 : 510 23.
20. Baldamus CA, Quellhorst E. Outcome of long-term haemofiltration. Kidney Int. 1985 28 (Suppl. 17 S41 S46.
21. Wizemann V, Lotz C, Techert F, Uthoff S. On line haemodiafiltration versus low-flux haemodialysis. A prospective randomised study. Nephrol. Dial. Transplant. 2000 15 : 43 8.
22. Locatelli F, Marcelli D, Conte F, Limido A, Malberti F, Spotti D. Comparison of mortality in ESRD patients on convective and diffusive extracorporeal treatments. Kidney Int. 1999 55 : 286 93.
23. Roy T. Technical and microbiological safety of online hemodiafiltration: a European perspective. Semin. Dial. 1999 12 : S81 87.
24. Pizzarelli F, Cerral T, Dattolo P, Tetta C, Maggiore Q. Convective treatments with on-line production of replacement fluid: a clinical experience lasting 6 years. Nephrol. Dial. Transplant. 1998 13 : 363 9.
25. Canaud B, Levesque R, Krieter D, Desmeules S, Chalabi L, Moragues H, Morena M, Cristol JP. On-line hemodiafiltration as routine treatment of end-stage renal failure: why pre- or mixed dilution mode is necessary in on-line hemodiafltration today? Blood Purif. 2004 22 (Suppl. 2 40 48.
26. Kerr PB, Argiles A, Flavier JL, Canaud B, Mion CM. Comparison of haemodialysis and hemodiafiltration: a long-term longitudinal study. Kidney Int. 1992 41 : 1035 40.
27. Spalding EM, Chamney PW, Farrington K. Phosphate kinetics during hemodialysis: evidence for biphasic regulation. Kidney Int. 2002 61 : 655 67.
28. Zehnder C, Gutzwiller JP, Renggli K. Hemodiafiltration - a new treatment option for hyperphosphatemia in hemodialysis patients. Clin. Nephrol. 1999 52 : 152 9.
29. Canaud B, Morena M, Cristol JP, Krieter D. Beta2-microglobulin, a uramic toxin with a double meaning. Kidney Int. 2006 69 : 1297 9.
30. Jaradat MI, Moe SM. Effect of haemodialysis membranes on beta 2-microglobulin amyloidosis. Semin. Dial. 2001 14 : 107 12.
31. Jadoul M, Garbar C, Vanholder R et al. Histological prevalence of beta2-microglobulin amyloidosis in haemodialysis: a prospective post mortem study. Kidney Int. 1997 51 : 1928 32.
32. Schoels M, Jahn B, Hug F et al. Stimulation of mononuclear cells by contact with cuprophan membranes: further increase of ß2-microglobulin synthesis by activated late complement components. Am. J. Kidney Dis. 1993 21 : 394 9.
33. Dember LM, Jaber BL. Dialysis-related amyloidosis: late finding or hidden epidemic Semin Dial. 2006 19 : 105 9.
34. Cheung AK, Rocco MV, Yan G et al. Serum beta-2 microglobulin levels predict mortality in dialysis patients - results of the HEMO study. J. Am. Soc. Nephrol. 2006 17 : 546 55.
35. Wiesholzer M, Harm F, Hauser AC et al. Inappropriately high plasma leptin levels in obese haemodialysis patients can be reduced by high flux haemodialysis and haemodiafiltration. Clin. Sci. 1998 94 : 431 53.
36. Lonneman G, Novick D, Rubinstein M et al. A switch to high-flux helixone membranes reverses suppressed interferon gamma production in patients on low-flux dialysis. Blood Purif. 2003 21 : 225 31.
37. Maduell F, Navarro V, Cruz MC et al. Osteocalcin and myoglobin removal in on-line hemodiafiltration versus low - and high-flux hemodialysis. Am. J. Kidney Dis. 2002 40 : 582 9.
38. Ward RA, Schmidt B, Hullin J et al. A comparison of on-line hemodiafiltration and high flux hemodialysis: a prospective clinical study. J. Am. Soc. Nephrol. 2000 11 : 2344 50.
39. Movilli E, Gaggiotti M, Maiorca R. Hemodiafiltration in hypotension - prone elderly uremic patients. Geriatr Urol Nephrol 1994 4 : 183 7.
40. Munoz R, Gallardo I, Valladers E et al. Online hemodiafiltration: 4 years of clinical experience. Hemodial. Int. 2006 1 (0 Suppl 1 S28 32.
41. Alitieri P, Sorba G, Bolasco P et al. Predilutional haemofiltration - the second Sardinian Multicentre Study: comparisons between haemofiltration and haemodialysis during identical KT/V and session times in a long-term cross-over study. Nephrol. Dial. Transplant. 2001 16 : 1207 13.
42. Donauer J, Schweiger C, Rumberger B, Krumme B, Bohler J. Reduction of hypotensive side effects during online-haemodiafiltration and low temperature haemodialysis. Nephrol. Dial. Transplant. 2003 18 : 1616 22.
43. Karemperis N, Sloth E, Jensen J. Predilution hemodiafiltration displays no hemodynamic advantage over low-flux hemodialysis under matched conditions. Kidney Int. 2004 67 : 1601 8.
44. European Best Practice Guidelines Working Group. European Best Practice Guidelines for haemodialysis. Section IV. Dialysis fluid purity. Nephrol. Dial. Transplant. 2002 17 (Suppl. 7 45 62.
45. Stenvinkel P, Heimbürger O, Lindholm B, Kaysen GA, Bergström J. Are there two types of malnutrition in chronic renal failure? Evidence for relationships between malnutrition, inflammation and atherosclerosis (MIA syndrome). Nephrol. Dial. Transplant. 2000 15 : 953 60.
46. Laude-Sharp M, Caroff M, Simard L, Pusineri C, Kazatchkine MD, Haeffner-Cavaillon N. Induction of IL-1 during hemodialysis: transmembrane passage of intact endotoxins (LPS). Kidney Int. 1990 38 : 1089 94.
47. Urena P, Herbelin A, Zingraff J et al. Permeability of cellulosic and non-cellulosic membranes to endotoxin subunits and cytokine production during in-vitro haemodialysis. Nephrol. Dial. Transplant. 1992 7 : 16 28.
48. Lonnemann G, Behme TC, Lenzner B et al. Permeability of dialyser membranes to TNF a inducing substances derived from water bacteria. Kidney Int. 1992 42 : 61 8.
49. Pereira BJ, Snodgrass BR, Hogan PJ, King AJ. Diffusive and convective transfer of cytokine-inducing bacterial products across hemodialysis membranes. Kidney Int. 1995 47 : 603 10.
50. Arduino MJ, Bland LA, McAllister SK, Favero MS. The effects of endotoxin- contaminated dialysate and polysulfone or cellulosic membranes on the release of TNF alpha during simulated dialysis. Artif. Organs 1995 19 : 880 6.
51. Tielemans C, Husson C, Schurmans T et al. Effects of ultrapure and non-sterile dialysate on the inflammatory response during in vitro haemodialysis. Kidney Int. 1996 49 : 236 43.
52. Schindler R, Krautzig S, Lufft V et al. Induction of interleukin-1 and interleukin-1 receptor antagonist during contaminated in-vitro dialysis with whole blood. Nephrol. Dial. Transplant. 1996 11 : 101 8.
53. Schhindler R, Christ-Kohlrausch F, Frei U, Shaldon S. Differences in permeability of high-flux dialyzer membranes for bacterial pyrogens. Clin. Nephrol. 2003 59 : 447 54.
54. Schindler R, Lonnemann G, Schaffer J, Shaldon S, Koch KM, Krautzig S. The effect of ultrafiltered dialysate on the cellular content of interleukin-1 receptor antagonist in patients on chronic hemodialysis. Nephron 1994 68 : 229 33.
55. Arizono K, Nomura K, Motoyama T et al. Use of ultrapure dialysate in reduction of chronic inflammation during hemodialysis. Blood Purif. 2004 22 (Suppl 2 26 9.
56. Lonnemann G, Sereni L, Lemke H-D, Tetta C. Pyrogen retention by highly permeable synthetic membranes during in vitro dialysis. Artif. Organs. 2001 25 : 951 60.
57. Sitter T, Bergner A, Schiffl H. Dialysate related cytokine induction and response to recombinant human erythropoietin in haemodialysis patients. Nephrol. Dial. Transplant. 2000 15 : 1207 11.
58. Schiffl H, Lang SM, Stratakis D, Fischer R. Effects of ultrapure dialysis fluid on nutritional status and inflammatory parameters. Nephrol. Dial. Transplant. 2001 16 : 1863 9.
59. Matsuhashi N, Yoshioka T. Endotoxin-free dialysate improves response to erythropoietin in hemodialysis patients. Nephron 2002 92 : 601 4.
60. Grooteman MP, Nube MJ, Daha MR et al. Cytokine profiles during clinical high flux dialysis: no evidence for cytokine generation by circulating monocytes. J. Am. Soc. Nephrol. 1997 8 : 1745 54.
61. Schouten WE, Grooteman MP, van Houte AJ, Schoorl M, van Limbeek J, Nube MJ. Effects of dialyser and dialysate on acute phase reaction in clinical bicarbonate dialysis. Nephrol. Dial. Transplant. 2000 15 : 379 84.
62. Furuya R, Kumagai H, Takahishi M, Sano K, Hishida A. Ultrapure dialysate reduces plasma levels of ß2-microglobulin and pentosidine in hemodialysis patients. Blood Purif. 2005 23 : 311 16.
63. Izuhara Y, Miyata T, Saito K et al. Ultrapure dialysate decreases plasma pentosidine, a marker of 'carbonyl stress Am. J. Kidney Dis. 2004 6 : 1024 9.
64. McKane W, Chandna SM, Tattersall JE, Greenwook RN, Farrington K. Identical decline of residual renal function in high-flux biocompatible hemodialysis and CAPD. Kidney Int. 2002 61 : 256 65.
65. Kleophas W, Haastert B, Backus G, Hilgers P, Westhoff A, van Endert G. Long-term experience with an ultrapure individual dialysis fluid with a batch type machine. Nephrol. Dial. Transplant. 1998 13 : 3118 25.
66. Schiffl H, Lang SM, Fischer R. Ultrapure dialysis fluid slows loss of residual renal function in new dialysis patients. Nephrol. Dial. Transplant. 2002 17 : 1814 18.
67. Hsu P-Y, Lin C-L, Yu C-C et al. Ultrapure dialysate improves iron utilization and erythropoietin response in chronic hemodialysis patients - a prospective cross-over study. J. Nephrol. 2004 17 : 693 700.
68. Gerdemann A, Wagner Z, Solf A et al. Plasma levels of advanced glycation end products during haemodialysis, haemodiafiltration and haemofiltration: potential importance of dialysate quality. Nephrol. Dial. Transplant. 2002 17 : 1045 9.
69. Bonforte G, Grillo P, Zerbi S, Surian M. Improvement of anemia in hemodialysis patients treated by hemodiafiltration with high-volume on-line-prepared substitution fluid. Blood Purif. 2002 20 : 357 63.